Case Study

Complete Response: Lymphoma Trial A Success For Five Patients

Source: Premier Research
Listening To Patients To Improve Clinical Trials

A trans-Atlantic study to evaluate an antibody for treatment of B-cell non-Hodgkins lymphoma is still almost three years from completing patient follow-up, but already it has succeeded beyond expectations in the form of five patients declared disease-free a year and counting.

The Phase II trial involved a CD19 antibody that was tested at 26 sites — 22 in Europe and four in the United States. Ninety-two patients enrolled in the study, which set out to evaluate the compound’s efficacy in treating four NHL subtypes: FL (follicular lymphoma), DLBCL (diffuse large B-cell lymphoma), MCL (mantle cell lymphoma), plus a fourth, a type of indolent NHL.

access the Case Study!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Premier Research